Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Common Equity: 2019-2025

Historic Common Equity for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $835.1 million.

  • Harmony Biosciences Holdings' Common Equity rose 39.93% to $835.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $835.1 million, marking a year-over-year increase of 39.93%. This contributed to the annual value of $659.2 million for FY2024, which is 41.15% up from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Common Equity stood at $835.1 million for Q3 2025, which was up 8.03% from $773.1 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' 5-year Common Equity high stood at $835.1 million for Q3 2025, and its period low was $107.9 million during Q1 2021.
  • For the 3-year period, Harmony Biosciences Holdings' Common Equity averaged around $592.3 million, with its median value being $538.6 million (2024).
  • Data for Harmony Biosciences Holdings' Common Equity shows a peak YoY soared of 126.21% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Harmony Biosciences Holdings' Common Equity stood at $186.5 million in 2021, then skyrocketed by 115.99% to $402.8 million in 2022, then climbed by 15.93% to $467.0 million in 2023, then soared by 41.15% to $659.2 million in 2024, then skyrocketed by 39.93% to $835.1 million in 2025.
  • Its Common Equity was $835.1 million in Q3 2025, compared to $773.1 million in Q2 2025 and $720.5 million in Q1 2025.